Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Neurogene Inc (NGNE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NGNE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.83
1 Year Target Price $43.83
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.43% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 286.53M USD | Price to earnings Ratio - | 1Y Target Price 43.83 |
Price to earnings Ratio - | 1Y Target Price 43.83 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 6.88 - 74.49 | Updated Date 07/4/2025 |
52 Weeks Range 6.88 - 74.49 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9701.19% |
Management Effectiveness
Return on Assets (TTM) -21.97% | Return on Equity (TTM) -34.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7465905 | Price to Sales(TTM) 309.76 |
Enterprise Value 7465905 | Price to Sales(TTM) 309.76 | ||
Enterprise Value to Revenue 8.07 | Enterprise Value to EBITDA -8.02 | Shares Outstanding 14262100 | Shares Floating 3232640 |
Shares Outstanding 14262100 | Shares Floating 3232640 | ||
Percent Insiders 9.28 | Percent Institutions 115.82 |
Upturn AI SWOT
Neurogene Inc
Company Overview
History and Background
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for neurological diseases. Founded in 2018, it aims to address unmet needs in inherited neurological disorders using AAV-based gene therapy.
Core Business Areas
- Gene Therapy Development: Focuses on developing and delivering gene therapies for rare neurological disorders.
- Platform Technology: Utilizes a proprietary adeno-associated virus (AAV) platform to deliver therapeutic genes.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of gene therapy candidates.
Leadership and Structure
The leadership team comprises experienced biotechnology executives and scientists. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- NGN-101 (for Rett syndrome): An investigational gene therapy for Rett syndrome. No market share data available as it's still in clinical trials. Competitors include companies developing therapies for Rett syndrome like Anavex Life Sciences (AVXL).
- NGN-111 (for Mucopolysaccharidosis Type A (MPS A)): An investigational gene therapy for MPS A. No market share data available as it's still in clinical trials. Competitors include BioMarin Pharmaceutical Inc. (BMRN) which has enzyme replacement therapy for MPS A.
- NGN-121 (for GACI): An investigational gene therapy for GACI. No market share data available as it's still in clinical trials. Competition includes companies developing treatments for GACI symptoms.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing success rates in clinical trials. The market faces challenges including high development costs and regulatory hurdles.
Positioning
Neurogene Inc. is positioned as an innovator in gene therapy for neurological disorders, focusing on rare diseases with high unmet medical needs. Its AAV-based platform provides a competitive advantage.
Total Addressable Market (TAM)
The gene therapy market is projected to reach billions of dollars. Neurogene Inc. targets specific rare neurological diseases, positioning it to capture a significant share if its therapies are approved. The specific TAM for each indication (Rett, MPS A, GACI) varies but represents a substantial opportunity.
Upturn SWOT Analysis
Strengths
- Proprietary AAV-based gene therapy platform
- Focus on rare neurological disorders
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialized products
- High development costs
- Regulatory risks
- Dependence on clinical trial outcomes
Opportunities
- Expansion into new neurological indications
- Strategic partnerships with pharmaceutical companies
- Accelerated regulatory pathways for rare diseases
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- BMRA
- AVXL
- SGTX
Competitive Landscape
Neurogene Inc. competes with established pharmaceutical companies and smaller biotech firms in the gene therapy space. Its competitive advantage lies in its proprietary AAV platform and focus on rare neurological diseases. Success depends on clinical trial outcomes and regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is measured by the advancement of its clinical pipeline and strategic partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and market adoption of its gene therapies. Analyst estimates are contingent on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for NGN-101, NGN-111, and NGN-121, and expanding the research and development pipeline.
Summary
Neurogene Inc. is a promising clinical-stage biotech company focusing on gene therapies for rare neurological disorders. While the company has no products currently approved, it possesses a potentially valuable AAV platform and targets indications with high unmet needs. Successful clinical trials and regulatory approvals are critical for future success. The main area of concern is cash burn related to research and development and the regulatory hurdles ahead.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The data provided is for informational purposes only and may not be entirely accurate or up-to-date. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurogene Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-03-07 | Founder, Executive Chair & CEO Dr. Rachel L. McMinn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 107 | Website https://www.neurogene.com |
Full time employees 107 | Website https://www.neurogene.com | ||
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.